sitagliptin/metformin clonmel 50 mg/1000 mg film-coated tablets
clonmel healthcare ltd - sitagliptin; metformin hydrochloride - film-coated tablet - 50 mg/1000 milligram(s) - metformin and sitagliptin
sitagliptin/metformin clonmel 50 mg/850 mg film-coated tablets
clonmel healthcare ltd - sitagliptin; metformin hydrochloride - film-coated tablet - 50 mg/850 milligram(s) - metformin and sitagliptin
sitagliptin/metformin hydrochloride grindeks 50 mg/1000 mg film-coated tablets
as grindeks - sitagliptin hydrochloride monohydrate; metformin hydrochloride - film-coated tablet - metformin and sitagliptin
sitagliptin/metformin hydrochloride grindeks 50 mg/850 mg film-coated tablets
as grindeks - metformin hydrochloride; sitagliptin hydrochloride monohydrate - film-coated tablet - metformin and sitagliptin
sitagliptin/metformin grindeks 50 mg/850 mg filmdragerad tablett
sitagliptin/metformin grindeks 50 mg/1000 mg filmdragerad tablett
sitagliptin aaa-pharma 50 mg filmtabletten
sitagliptin aaa-pharma 25 mg filmtabletten
sitagliptin aaa-pharma 100 mg filmtabletten
metformin hydrochloride tablet, film coated
legacy pharmaceutical packaging, llc - metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - metformin hydrochloride 500 mg - metformin hydrochloride tablet is indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus. metformin hydrochloride extended-release tablet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. metformin hydrochloride tablets and metformin hydrochloride extended-release tablets are contraindicated in patients with: 1. severe renal impairment (egfr below 30 ml/min/1.73m 2 (see warnings and precautions ). 2. known hypersensitivity to metformin hydrochloride. 3. acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin.